BioCentury | Sep 9, 2020
Product Development

COVID-19 roundup: SpyBiotech-Serum Institute of India send HBV-based COVID-19 vaccine to clinic; plus Vaxart, Inovio-Thermo Fisher and RedHill

...protein “superglue” technology that covalently links the SARS-CoV-2 spike protein to the surface of a hepatitis B surface antigen (HBsAg)...
BioCentury | May 12, 2020
Product Development

Vaccine prospects for COVID-19: learnings from a 40-year biotech journey that’s still in progress

...One of the first was for hepatitis B. Here the hepatitis B virus surface antigen (HbSag...
BioCentury | Apr 17, 2020
Product Development

Vir’s dose response, safety data spur combo studies of Alnylam-partnered HBV therapy

...Phase I/II data unveiled Wednesday showed that VIR-2218 alone led to durable, dose-dependent reductions in HBsAG...
...lowest dose had HBsAg levels about 82.6% lower than baseline. The 50 mg dose reduced HBsAG...
...healthy volunteers given a single 900 mg dose. Targets ALT - Alanine transaminase HBsAg - Hepatitis B surface antigen...
BioCentury | Jan 11, 2020
Company News

Led by Blatt, Aligos reunites Alios team to develop functional cure for HBV

...added. Blatt said that to treat HBV, replication of the virus must be blocked, and HBsAg...
...cure,” Blatt said. One of Aligos’ three therapies is ALG-ASO, an antisense oligonucleotide (ASO) against HBsAg...
...Targets: HBsAg - Hepatitis B surface antigen; THRB - Thyroid hormone receptor β Elizabeth S. Eaton, Staff Writer Alios BioPharma Inc. Hepatitis B surface antigen (HBsAg)...
BioCentury | Nov 1, 2019
Clinical News

Hepatitis D draft guidance outlines surrogate endpoints

...Sarasar also has Fast Track designation from FDA. Targets: ALT - Alanine transaminase; HBsAg - Hepatitis B surface antigen...
BioCentury | Oct 31, 2019
Company News

Dicerna’s latest deal lands $200M, Roche as partner in HBV

...continue partnering with larger pharmas in wider therapeutic areas. DCR-HBVS targets a part of the HBsAg...
...has a long duration of action and leads to a high reduction in expression of hepatitis B surface antigen...
...Phase II trial’s prespecified threshold required to move forward. Elizabeth S. Eaton, Staff Writer DCR-HBV, DCR-HBVS Roche Dicerna Pharmaceuticals Inc. Hepatitis B surface antigen (HBsAg)...
BioCentury | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

...HBV infection is to combine therapies targeting multiple aspects of HBV biology, particularly viral replication, HBsAg...
...of business development and market analytics. Sofia was its SVP of chemistry. Targets: HBsAg - Hepatitis B surface antigen...
BioCentury | Sep 4, 2019
Financial News

Vir plots IPO as more programs near clinic

...at least three others. VIR-2218, an siRNA-based therapy targeting HBV, has led to reductions in HBsAg...
BioCentury | Jul 11, 2019
Distillery Therapeutics

Adoptive transfer with T cells expressing anti-HBV TCRs for HBV

...infection. Incubation of HBV-infected human liver cells with HBV-targeted T cells reduced hepatocyte levels of HBsAg...
...as secreted and intracellular viral DNA levels. The engineered T cells decreased viral load and HBsAg...
...HBV receptors on mature hepatocytes, in Phase II testing for HBV and HDV infections. TARGET/MARKER/PATHWAY: Hepatitis B surface antigen (HBsAg)...
BioCentury | Mar 22, 2019
Financial News

Dynavax commercializing Heplisav-B with $75M debt financing

...Programmed cell death 1 (PDCD1; CD279); TLR9 - Toll-like receptor 9 Mark Zipkin, Staff Writer Heplisav-B (Brand), HBsAg-1018...
Items per page:
1 - 10 of 273